Search research articles
Contact Us
Filters
Showing results (31-40 of 325) with videos related to
Page
of 33
Sort By:
Blood Cancer Discovery
|
June 26, 2026
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?
Alberto J Arribas, Carlo Visco, Francesco Bertoni
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2014
Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas
Emanuele Zucca, Francesco Bertoni, Barbara Vannata, et al.
Hematological Oncology
|
January 13, 2006
Update on the molecular biology of mantle cell lymphoma
Francesco Bertoni, Andrea Rinaldi, Emanuele Zucca, et al.
Hematology/Oncology Clinics of North America
|
October 29, 2008
Marginal zone lymphomas
Emanuele Zucca, Francesco Bertoni, Anastasios Stathis, et al.
Cancer Treatment Reviews
|
September 6, 2020
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences
Laura Carrassa, Ilaria Colombo, Giovanna Damia, et al.
Cancers
|
April 23, 2022
Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades
Sara Napoli, Nicolas Munz, Francesca Guidetti, et al.
Pharmacology & Therapeutics
|
April 20, 2020
An overview on anti-tubulin agents for the treatment of lymphoma patients
Marilia Barreca, Anastasios Stathis, Paola Barraja, et al.
Frontiers in Oncology
|
December 21, 2020
DNA Copy Number Changes in Diffuse Large B Cell Lymphomas
Luciano Cascione, Luca Aresu, Michael Baudis, et al.
International Journal of Molecular Sciences
|
February 9, 2020
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Chiara Tarantelli, Antonio Lupia, Anastasios Stathis, et al.
Cancer Journal (Sudbury, Mass.)
|
August 1, 2020
Marginal Zone Lymphomas
Francesco Bertoni, Davide Rossi, Markus Raderer, et al.
Page
of 33
Search research articles
Search
Showing results (31-40 of 325) with videos related to
Sort By:
Page
of 33
Blood Cancer Discovery
|
June 26, 2026
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?
Alberto J Arribas, Carlo Visco, Francesco Bertoni
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2014
Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas
Emanuele Zucca, Francesco Bertoni, Barbara Vannata, et al.
Hematological Oncology
|
January 13, 2006
Update on the molecular biology of mantle cell lymphoma
Francesco Bertoni, Andrea Rinaldi, Emanuele Zucca, et al.
Hematology/Oncology Clinics of North America
|
October 29, 2008
Marginal zone lymphomas
Emanuele Zucca, Francesco Bertoni, Anastasios Stathis, et al.
Cancer Treatment Reviews
|
September 6, 2020
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences
Laura Carrassa, Ilaria Colombo, Giovanna Damia, et al.
Cancers
|
April 23, 2022
Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades
Sara Napoli, Nicolas Munz, Francesca Guidetti, et al.
Pharmacology & Therapeutics
|
April 20, 2020
An overview on anti-tubulin agents for the treatment of lymphoma patients
Marilia Barreca, Anastasios Stathis, Paola Barraja, et al.
Frontiers in Oncology
|
December 21, 2020
DNA Copy Number Changes in Diffuse Large B Cell Lymphomas
Luciano Cascione, Luca Aresu, Michael Baudis, et al.
International Journal of Molecular Sciences
|
February 9, 2020
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Chiara Tarantelli, Antonio Lupia, Anastasios Stathis, et al.
Cancer Journal (Sudbury, Mass.)
|
August 1, 2020
Marginal Zone Lymphomas
Francesco Bertoni, Davide Rossi, Markus Raderer, et al.
Page
of 33